These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 15183078)

  • 21. Chronic angiotensin II antagonism with losartan in one-kidney, one clip hypertensive rats: effect on cardiac hypertrophy, urinary sodium and water excretion and the natriuretic system.
    Garcia R; Bonhomme MC; Diebold S
    J Hypertens; 1996 Jan; 14(1):81-9. PubMed ID: 12013499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes.
    Komers R; Simkova R; Kazdova L; Ruzickova J; Pelikanova T
    J Renin Angiotensin Aldosterone Syst; 2004 Mar; 5(1):33-8. PubMed ID: 15136972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
    Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
    J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan.
    Kakimoto T; Okada K; Hirohashi Y; Relator R; Kawai M; Iguchi T; Fujitaka K; Nishio M; Kato T; Fukunari A; Utsumi H
    J Endocrinol; 2014 Jul; 222(1):43-51. PubMed ID: 24781258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis.
    Tylicki L; Renke M; Rutkowski P; Rutkowski B; Lysiak-Szydłowska W
    Med Sci Monit; 2005 Apr; 11(4):PI31-7. PubMed ID: 15795705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes seen in the aging kidney and the effect of blocking the renin-angiotensin system.
    Inserra F; Basso N; Ferder M; Userpater M; Stella I; Paglia N; Inserra P; Tenembaum D; Ferder L
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):341-6. PubMed ID: 19574289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B; Gleim G; Panish J
    Curr Med Res Opin; 2004 Dec; 20(12):1909-17. PubMed ID: 15701209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
    Deb DK; Sun T; Wong KE; Zhang Z; Ning G; Zhang Y; Kong J; Shi H; Chang A; Li YC
    Kidney Int; 2010 Jun; 77(11):1000-9. PubMed ID: 20182412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of losartan on the glomerular protein expression profile of type 2 diabetic KKAy mice.
    Fan QL; Yang G; Liu XD; Ma JF; Feng JM; Jiang Y; Wang LN
    J Nephrol; 2013; 26(3):517-26. PubMed ID: 22684654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
    Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: a further experimental insight into the pathophysiology of diabetic nephropathy.
    Morano S; Cipriani R; Santangelo C; Fallarino M; Carnovale A; Mandosi E; Gatti A; Sensi M; Di Mario U
    Clin Ter; 2008; 159(3):151-4. PubMed ID: 18594743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
    Agha A; Bashir K; Anwar E
    Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK
    Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.